These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23565885)

  • 1. Different targets of anti-glucocorticoid treatment have been proposed, acting at supra-hypothalamic, HPA axis, glucocorticoid receptor and post-receptor levels.
    Di Marzo V
    Recent Pat CNS Drug Discov; 2013 Apr; 8(1):1. PubMed ID: 23565885
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
    Skundric DS
    Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
    [No Abstract]   [Full Text] [Related]  

  • 3. Targets of anti-glucocorticoid therapy for stress-related diseases.
    Martocchia A; Stefanelli M; Falaschi GM; Toussan L; Rocchietti March M; Raja S; Romano G; Falaschi P
    Recent Pat CNS Drug Discov; 2013 Apr; 8(1):79-87. PubMed ID: 23489288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders.
    Martocchia A; Curto M; Toussan L; Stefanelli M; Falaschi P
    Recent Pat CNS Drug Discov; 2011 Sep; 6(3):196-204. PubMed ID: 21834781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New frontiers in G protein-coupled receptor regulation of neurological disorders.
    Maudsley S
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):525. PubMed ID: 20632974
    [No Abstract]   [Full Text] [Related]  

  • 6. Microglia--a therapeutic target in neurological diseases and disorders.
    Kaur C; Ling EA
    CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):719. PubMed ID: 24047518
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting epigenetics in nervous system disease.
    Zhang R; Lu J; Kong X; Jin L; Luo C
    CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):126-41. PubMed ID: 23244434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs as CNS Drug Targets.
    Gurwitz D
    Drug Dev Res; 2016 Nov; 77(7):331-335. PubMed ID: 27569840
    [No Abstract]   [Full Text] [Related]  

  • 9. Trace amine receptors as targets for novel therapeutics: legend, myth and fact.
    Branchek TA; Blackburn TP
    Curr Opin Pharmacol; 2003 Feb; 3(1):90-7. PubMed ID: 12550748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid Negative Feedback in Regulation of the Hypothalamic-Pituitary-Adrenal Axis in Rhesus Monkeys With Various Types of Adaptive Behavior: Individual and Age-Related Differences.
    Goncharova N; Chigarova O; Rudenko N; Oganyan T
    Front Endocrinol (Lausanne); 2019; 10():24. PubMed ID: 30814974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of nanotechnology in developing new therapies for diseases of the nervous system.
    Jain KK
    Nanomedicine (Lond); 2006 Jun; 1(1):9-12. PubMed ID: 17716203
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting kinin receptors for the treatment of neurological diseases.
    Rodi D; Couture R; Ongali B; Simonato M
    Curr Pharm Des; 2005; 11(10):1313-26. PubMed ID: 15853687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special Issue: Comorbidities in stroke outcomes: Novel therapeutic targets.
    Paul S; Candelario-Jalil E
    Exp Neurol; 2021 Jun; 340():113641. PubMed ID: 33689986
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging Epigenetic Therapies in Neuroscience: Focus on Bromodomain-Containing Drug Targets.
    Wahlestedt C
    Neuropsychopharmacology; 2017 Jan; 42(1):374. PubMed ID: 27909334
    [No Abstract]   [Full Text] [Related]  

  • 15. Modifying protein misfolding.
    Jones D
    Nat Rev Drug Discov; 2010 Nov; 9(11):825-7. PubMed ID: 21030987
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits.
    Maric NP; Adzic M
    Psychiatr Danub; 2013 Sep; 25(3):299-305. PubMed ID: 24048401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
    Gordijn MS; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
    Cochrane Database Syst Rev; 2012 May; (5):CD008727. PubMed ID: 22592733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain transporters: From genes and genetic disorders to function and drug discovery.
    Vandenberg RJ; Ryan R; Broer S
    Neurochem Int; 2016 Sep; 98():1-3. PubMed ID: 27475459
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential drug targets and treatment of schizophrenia.
    Kumar A; Yadav M; Parle M; Dhingra S; Dhull DK
    Inflammopharmacology; 2017 Jun; 25(3):277-292. PubMed ID: 28353125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules.
    Chesnokova V; Melmed S
    Endocrinology; 2002 May; 143(5):1571-4. PubMed ID: 11956136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.